RxDoctor Payments Data

Konstantin Tachan, DO

Family Medicine · Sarasota, FLNPI 1679100887

Payments from drug & device makers

$850in general payments, 2019–2025

Across 36 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$332
  • Exact Sciences$88
  • Pfizer$59
  • Lilly USA, LLC$58
  • GSK$55
  • AstraZeneca$51
  • plus $208 from 8 others

What the payments were for

  • Food & beverage$81896%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$850 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$346,182
Medicare patients
970
Services billed
6,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$64,748
EliquisApixaban50$47,336
JardianceEmpagliflozin23$37,981
RybelsusSemaglutide13$34,416
EntrestoSacubitril/Valsartan15$17,689
MounjaroTirzepatide11$11,144
PaxlovidNirmatrelvir/Ritonavir50$4,288
SynthroidLevothyroxine Sodium43$3,669
Rosuvastatin Calcium145$2,850
Atorvastatin Calcium286$2,800
Sertraline Hcl138$2,634
Doxepin Hcl19$1,920
Levothyroxine Sodium226$1,752
Omeprazole101$1,591
Gabapentin101$1,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$332$99,16452 claims
PfizerEliquis, Paxlovid$59$51,624100 claims
Boehringer IngelheimJardiance$30$37,98123 claims
Lilly USA, LLCMounjaro$58$11,14411 claims
Almatica Pharma LLCSertraline Hcl$17$2,634138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →